Acute Viral Encephalitis
NEJM 379:357-366, Tyler,K.L., 2018
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Second Drug Okayed for Rare Central Nervous System Disease
JAMA 324:224, Jaklevic, M.C., 2020
Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Multiple Sclerosis
NEJM 378:169-180, Reich, D.S.,et al, 2018
Misdiagnosis of Multiple Sclerosis
Neurol 92:15-16, Brownlee, W.J., 2018
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011
Disability, distress and unemployment in neurology outpatients with symptoms unexplained by organic disease
JNNP 82:810-813, 710, Carson, A.,et al, 2011
Generic Antiepileptic Drugs and Associated Medical Resource Utilization in the United States
Neurol 74:1566-1574, 1562, Labiner,D.M., et al, 2010
Triptan Therapy in Migraine
NEJM 363:63-70, Loder,E., 2010
The Risks and Costs of Multiple-Generic Substitution of Topiramate
Neurol 72:2122-2129, Duh,M.S.,et al, 2009
Diagnosis and Management of Neuropathic Pain
BMJ 339:391-395, Freynhagen,R. &Bennett,M.I., 2009
The Value of Specifying Brand-Name Antiepileptic Drugs
Arch Neurol 66:1415-1416, 1418, Ng,Y., 2009
Generic Anticonvulsant Use in Children: Do We Have Evidence to Recommend Brand Formulations?
Arch Neurol 66:1417-1418, Hamiwka,L., 2009